As the global pharmaceutical landscape undergoes a period of unprecedented transformation—driven by the rapid integration of artificial intelligence, a shift toward complex biologics, and an evolving regulatory environment—industry leaders are set to converge in New Orleans. From October 25–28, 2026, the Ernest N. Morial Convention Center will host AAPS PharmSci 360, an event that has solidified its reputation as the premier "science-first" gathering for pharmaceutical scientists.
This year’s edition promises to be more than just a conference; it serves as a critical nexus for researchers, executives, and regulatory experts to dissect the lifecycle of drug development. With thousands of attendees representing the spectrum of the industry—from nimble startups to multinational pharmaceutical giants—PharmSci 360 is positioned to set the agenda for the next decade of therapeutic discovery.
The Strategic Imperative: Why PharmSci 360 Matters
The pharmaceutical industry is currently grappling with the "speed-to-market" dilemma. How can companies compress development timelines without compromising safety or regulatory compliance? The 2026 program is curated to address this central question, moving beyond theoretical discussions to provide actionable insights.
Organizations like AstraZeneca, Merck, the Mayo Clinic, and Rx-360 will be front and center, sharing findings that bridge the gap between bench science and clinical reality. By fostering a collaborative environment, the event aims to tackle the multifaceted challenges of drug delivery, immunogenicity, and the ethical integration of new technological platforms.
Chronology of Innovation: A Three-Day Deep Dive
The conference schedule is meticulously structured to provide a comprehensive view of the drug development lifecycle, ensuring that researchers at every stage—from early-stage discovery to late-stage clinical trials—walk away with tangible takeaways.
Monday, October 26: The Foundations of Development
Monday’s agenda kicks off with a hard look at the structural impediments to drug development.
- Executive Insights: The Executive Track will feature an "autopsy" of drug development delays. Featuring experts like Dr. Leigh Verbois (CEO, Rx-360) and Teresa R. Henry (President, Blue Oaks Biotech), the session aims to diagnose the systemic inefficiencies that stifle speed.
- Regulatory Readiness: As the industry adapts to the ICH S12 guidelines, Dr. Nagendra Chemuturi (Eli Lilly) will provide a roadmap for designing regulatory-ready biodistribution and persistence strategies.
- Advanced Modeling: The day also delves into biological systems, with Dr. Kim L.R. Brouwer (UNC Eshelman School of Pharmacy) exploring the future of liver-on-a-chip technology and sandwich-cultured hepatocytes—tools essential for predictive toxicology.
Tuesday, October 27: The Era of Advanced Methodologies
Tuesday focuses on the "New Approach Methodologies" (NAMs) that are poised to replace traditional animal models.
- Quantitative Toxicology: Dr. Jeffrey Woodhead (Simulations Plus) will showcase how quantitative systems toxicology can revolutionize how we understand drug safety.
- Clinical Frontiers: A highlight for many will be the discussion on the clinical consequences of GLP-1-induced gastric emptying delays, presented by Dr. Jessica Atieh (Mayo Clinic). This session is particularly timely given the explosion of interest in metabolic therapeutics.
- Nanomedicine: Dr. Annette Bak (AstraZeneca) will provide a masterclass in the translation of nanomedicine, guiding attendees from initial design parameters to successful therapeutic outcomes.
Wednesday, October 28: Looking Toward the Future
The final day addresses the complexity of modern biologics and the necessity of global regulatory alignment.
- The Pediatric Challenge: In a highly anticipated "Hot Topic" session, Dr. John J. Alexander (FDA) and Dr. Alysha Croker (Health Canada) will debate whether global regulators are finally on the same page regarding pediatric drug data—a persistent hurdle for global drug launches.
- Precision Dosing: Dr. Ran Li (Genentech) will discuss the modeling strategies required for multispecific biologics, a field that requires a departure from traditional "one-size-fits-all" dose selection.
Innovator-Curated Tracks: A New Paradigm
A significant departure for the 2026 conference is the introduction of Innovator-Curated Tracks. Rather than a generalist approach, AAPS has empowered field leaders to build dedicated sessions around the most pressing issues in science today.
On October 26, Brian Nosek will lead a session on Research Integrity. As the scientific community faces increased scrutiny regarding reproducibility and data transparency, this track offers a vital forum for discussing best practices at the institutional and individual levels.
Following this, on October 28, Dr. Thomas Hartung (Johns Hopkins University) will spearhead the track on New Approach Methodologies (NAMs). This series will integrate the latest findings from Tulane University and emerging innovators like 28Bio and VeriSim Life, marking a definitive shift toward non-animal testing models in regulatory submissions.
Expert Perspectives: Plenaries and Partnerships
The keynote addresses are designed to frame the broader context of healthcare innovation. Dr. Julie Gerberding (FNIH), a titan in the public health sphere, will open the conference on October 25. Her insights into the future of the FNIH and its role in accelerating discovery are expected to set a high bar for the proceedings. Closing the event, Dr. David Berry (Averin Capital) will pivot to the financial and technological landscape, offering a venture capitalist’s perspective on the technologies that will define the market in 2030 and beyond.
Furthermore, a new partnership with the United States Pharmacopeia (USP) adds a layer of practical utility to the event. For the first time, USP scientists will conduct sessions directly within the exhibit hall. These sessions will focus on the nuts-and-bolts of pharmaceutical manufacturing—complex generics, excipient quality, and inhalation standards—providing engineers and bench scientists with immediate, applicable knowledge.
Implications for the Industry
The gathering in New Orleans represents a broader shift in how the industry views "success." The focus is moving away from purely chemical breakthroughs toward a holistic integration of data science, regulatory foresight, and ethical research practices.
Bridging the Knowledge Gap
The Careers 360 initiative, running concurrently in the exhibit hall, reflects a commitment to the "human" element of the industry. By offering AI skill-building workshops, credentialing advice, and resume reviews, the conference acknowledges that the pace of innovation requires a workforce that is constantly retooling. Whether it is an early-career researcher learning to navigate IP law or a seasoned executive pivoting to a startup, the resources provided at the exhibit hall are designed to foster professional longevity.
The Role of Industry Stalwarts and Emerging Players
The exhibit hall will serve as a visual map of the industry’s trajectory. Attendees will have the opportunity to engage with long-standing industry leaders like Thermo Fisher Scientific, Agilent, and SCIEX, while also exploring the disruptive technologies offered by companies like 10x Genomics and IQVIA. This mix of legacy expertise and fresh innovation is what makes PharmSci 360 a unique ecosystem.
Conclusion: Securing Your Place in the Future
As the industry prepares for the upcoming gathering, the message is clear: the challenges facing pharmaceutical development—whether they be regulatory, technological, or ethical—cannot be solved in silos. The cross-pollination of ideas facilitated by AAPS PharmSci 360 is essential for maintaining the momentum of global drug discovery.
For those looking to influence the trajectory of their research, network with the leading minds in the field, and stay ahead of the regulatory curve, the October 25–28 window in New Orleans is an essential commitment.
Join the conversation at AAPS PharmSci 360.
About the Author
